Zydus Lifesciences News: There may be a lot of movement in the shares of pharma sector giant Zydus Lifesciences when the stock market opens on the next trading day because good news has come for it from America. The company has received approval for clinical trials of a drug from the US market regulator FDA (Food and Drug Administration). The company has given this information in its exchange filing today. At present its shares are priced at Rs 994.15, which is its closing price on BSE on Friday, January 17. Shares of Zydus Lifesciences have strengthened by more than two percent this year.
For which medicine has Zydus Lifesciences received approval?
Zydus Lifesciences has received Phase II(b) clinical trial approval for Usnoblast from the US drug regulator FDA. This medicine is for the treatment of amyotrophic lateral sclerosis (ALS). ALS is a disease related to the nervous system that affects the nerve cells of the brain and spinal cord. Due to this, control over the muscles is lost. It is considered a very serious disease and according to many medical reports there is no cure for it yet.
How were the shares in one year?
Shares of Zydus Lifesciences have earned handsome earnings for investors. Last year on January 18, 2024, it was at Rs 685.85, which is a one-year low for its shares. From this low level, it jumped by more than 93 percent in 7 months and on August 9, 2024, it reached a price of Rs 1323.90, which is a record high for its shares. However, the rise in shares stopped here and at present it is about 25 percent downside from this high.
Fraud will be curbed! Bank calls will come from these numbers only, strict rules made for companies too
Tech Mahindra Salary Hike: Operating margin will be hit if salary is increased, should investors be worried?
Voda Idea will get relief! Work going on at a fast pace on this proposal for AGR dues
Disclaimer: The information provided here is being provided for information only. It is important to mention here that investing in the market is subject to market risks. As an investor, always consult an expert before investing money. Moneycontrol never advises anyone to invest money here.